Kuntai capsule to alleviate hypoestrogenic symptoms in patients with endometriosis and adenomyosis treated with long-acting GnRHa: a prospective, multicenter, randomized, controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091803

Enrollment

Unknown

Registered

2024-11-04

Start date

2024-11-04

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis and adenomyopathy

Interventions

Experimental group (Kuntai group):Noride 10.8mg was injected subcutaneously once within 3 days of menstruation. After 4 weeks of Noride injection, he was returned to the hospital, serum FSH, LH and E2

Control group (Progynova group):Noride 10.8mg was injected subcutaneously once within 3 days of menstruation. After 4 weeks of Noride injection, the serum FSH, LH and E2 levels were detected, gynecolo

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: ? Women aged 20-50 years; ? Ultrasound or MRI indicated endometriosis or adenomyosis of uterus.

Exclusion criteria

Exclusion criteria: ? History of malignant tumor; ? severe hepatic and renal insufficiency; ? are using hormone drugs; ?Patients with other serious organ diseases; ? Allergic to known components of the test drug.

Design outcomes

Primary

Measure	Time frame
Changes in Kupperman scores;	—

Secondary

Measure	Time frame
Serum CA125;Serum estradiol;	—

Countries

China

Contacts

Public Contactlinyun

Guangdong Provincial People’s Hospital

18688886223@163.com+86 186 8888 6223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026